Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
HNGE shareholder filed a Rule 144 notice to sell 373,955 Class A shares, with an aggregate market value of 15,272,322.2. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash. The proposed sales are expected to begin around 11/18/2025 through broker Merrill Lynch on the NYSE. The notice states that 37,919,155 Class A shares are outstanding, giving context for the size of this planned sale.
HNGE insider filed a Form 144 notice to sell 2,187 shares of common stock, with an aggregate market value of $88,476.40. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 07/01/2024, with full payment made that same day. The filing notes that 37,919,155 shares of this class are outstanding and includes the standard representation that the seller is not aware of any undisclosed material adverse information about HNGE’s operations, including where a Rule 10b5-1 trading plan is used.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh filed an amended Schedule 13G reporting their beneficial ownership of 1,293,007 shares of Hinge Health, Inc. Class A common stock, representing 4.75% of the class. They report shared power to vote and dispose of all of these shares, with no sole voting or dispositive power. The group states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hinge Health. The ownership percentage is calculated using 37,919,155 shares of common stock outstanding as of September 30, 2025, as referenced from the company’s Form 10-Q.
Hinge Health (HNGE) announced a share repurchase authorization. The Board approved a program to buy back up to $250.0 million of Class A common stock. The company disclosed that repurchases may occur in the open market, through privately negotiated transactions, or by other methods, and may be conducted in accordance with Rule 10b-18. The company may also use Rule 10b5-1 plans.
The authorization does not obligate Hinge Health to repurchase any specific amount and can be modified, suspended, or terminated at any time at the Board’s discretion. The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.
Hinge Health (HNGE) reported Q3 2025 results showing strong top-line growth with ongoing investment-driven losses. Revenue reached $154.2 million, up from $100.6 million a year ago, as more clients and members used its musculoskeletal care platform. Gross profit was $126.2 million.
Operating loss was $6.1 million and net loss was $1.8 million for the quarter. For the first nine months of 2025, revenue totaled $417.1 million versus $273.1 million a year ago, while a large increase in operating expenses, including stock-based compensation, drove a net loss of $560.4 million. The company ended the quarter with $261.3 million in cash and cash equivalents and $233.8 million in marketable securities, and generated $107.5 million of operating cash flow year-to-date. Deferred revenue rose to $299.7 million, reflecting billed but not yet recognized subscription revenue.
Hinge Health, Inc. furnished an update announcing it issued a press release with financial results for the third quarter ended September 30, 2025, and will host a conference call on November 4, 2025 at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.
The company noted that the press release and call reference non-GAAP financial measures, with reconciliations to GAAP provided in the press release. Hinge Health also posted supplemental investor materials on its investor relations website (ir.hingehealth.com) and stated it uses that site to disclose material information and comply with Regulation FD.
The information was furnished under Items 2.02 and 7.01, and the press release was included as Exhibit 99.1.
Gabriel M.I. Mecklenburg, Executive Chairman & Co-Founder of Hinge Health, Inc. (HNGE), reported multiple option exercises on 09/24/2025. The Form 4 shows exercises of several stock options at strike prices between $0.30 and $1.90, resulting in the acquisition of Class B Common Stock and conversion rights into Class A Common Stock.
Following the transactions, the reporting person directly owns large quantities of Class A and Class B shares: 1,092,119 Class A shares held indirectly by GRAT and 383,592 Class A shares held indirectly by a Family Trust, plus multiple blocks of Class B shares received from exercised options (examples: 107,813, 84,320, 42,969, 60,157, 31,548). Some shares are subject to an underwriter lock-up after the issuer's IPO, and 944,250 PSUs are included among holdings and vest per award terms.
Hinge Health, Inc. Schedule 13G shows Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh jointly report beneficial ownership of 1,363,061 shares of the issuer's Class A common stock, representing 5.51% of the outstanding class. The filing states these shares are held with shared voting and dispositive power and that the percentage is calculated using 24,749,541 outstanding shares from the issuer's 8-A12B filed May 19, 2025. The signatories certify the holdings were acquired and are held in the ordinary course of business.
Coatue and affiliated entities report a significant passive stake in Hinge Health's Class A stock. The filing discloses aggregate beneficial ownership of 2,960,200 shares by Coatue Management and Philippe Laffont, equal to 9.9% of the Class A shares. Two affiliated vehicles are separately disclosed: Coatue Growth Fund IV LP holds 2,401,696 shares (8.1%) and Coatue US 70 LLC holds 2,300,512 shares (7.9%). The reported shares include those directly held and those issuable upon conversion of Class B common stock, and all reported holdings are shown as shared voting and dispositive power with no sole voting or sole dispositive power.
Insight Entities disclosed beneficial ownership stakes in Hinge Health, Inc. (HNGE) via a joint Schedule 13G filing. The filing lists multiple reporting persons affiliated with Insight Partners, including IVP X funds, Insight Venture Associates entities and Insight Holdings Group, and gives the principal offices as c/o Insight Partners, 1114 Avenue of the Americas, New York.
The Reporting Persons report beneficial ownership of 11,029,604 shares of Class B Common Stock that are treated as issuable into Class A Common Stock on a one-for-one basis for percent calculations. On that basis, the Reporting Persons represent approximately 28.8% of the Class A Common Stock (calculated using 27,223,448 shares of Class A outstanding plus the Reporting Persons’ Class B shares). Individual cover-page totals include: IVP X (5,508,113 shares, 14.4%), IVP Cayman X (4,516,719 shares, 11.8%), IVP Delaware X (873,715 shares, 2.3%), IVP X Co-Investors (131,057 shares, 0.3%), and consolidated Insight entities holding the full 11,029,604 shares (28.8%). The filing is a joint submission and attaches a joint filing agreement as Exhibit 99.1.